Corcept Therapeutics CORT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's operating cash flow?
- Corcept Therapeutics (CORT) reported operating cash flow of -$16.77M in Q1 2026.
- How has Corcept Therapeutics's operating cash flow changed year-over-year?
- Corcept Therapeutics's operating cash flow decreased by 451.6% year-over-year, from $4.77M to -$16.77M.
- What is the long-term trend for Corcept Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Corcept Therapeutics's operating cash flow has grown at a -4.1% compound annual growth rate (CAGR), from $167.89M to $142M.
- What does operating cash flow mean?
- The net cash generated from daily business operations.
- How do you interpret operating cash flow?
- Higher values indicate strong operational health and the ability to self-fund growth.
- How does operating cash flow compare across companies?
- A fundamental metric for all public companies; essential for assessing business sustainability.